Drug Patents owned by Vertex Pharms

1. Drug name - INCIVEK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 years from now)

CN1869061B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN101633636A VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN1869061A VERTEX PHARMS Mimic Peptide Protease Inhibitor
Oct, 2016

(5 years ago)

CN101633636B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN1451014A VERTEX PHARMS Mimic Peptide Protease Inhibitor
Oct, 2016

(5 years ago)

CN100522991C VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2016

(5 years ago)

CN101693672A VERTEX PHARMS Peptide-Mimetic Protease Inhibitors
Oct, 2017

(4 years ago)

CN101693672B VERTEX PHARMS Peptidomimetic Protease Inhibitors
Oct, 2017

(4 years ago)

IN212710B VERTEX PHARMS Peptidomimetic Compounds And Pharmaceutical Compositions
Aug, 2021

(1 year, 1 month ago)

IN200300242P2 VERTEX PHARMS Peptidomimetic Compounds And Pharmaceutical Compositions
Aug, 2021

(1 year, 1 month ago)

EP1878720A1 VERTEX PHARMS Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

EP1958956A2 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

EP2368877A1 VERTEX PHARMS Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection
Aug, 2021

(1 year, 1 month ago)

EP1958956B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

EP1878720B1 VERTEX PHARMS Process For Preparing Chiral Bicycloprolinates As Intermediates For The Preparation Of Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

EP2368877B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors And Intermediates For Their Preparation As Treatment For Hcv Infection
Aug, 2021

(1 year, 1 month ago)

EP1958956A3 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

EP1320540B9 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

EP1320540B1 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

EP1320540A2 VERTEX PHARMS Peptidomimetic Protease Inhibitors
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms May, 2028

(5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
375MG TABLET;ORAL Discontinued

2. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

CN102652128A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

IN282654B VERTEX PHARMS Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816A2 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2489659B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; Method of treating cystic fibrosis; Method of treating cystic fibrosis; method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.